Free Trial
ASX:ARX

Aroa Biosurgery (ARX) Stock Price, News & Analysis

About Aroa Biosurgery Stock (ASX:ARX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
$193.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and OviTex and OviTex PRS, a reinforced bioscaffolds for use in hernia repair and abdominal wall reconstruction, as well as breast reconstruction. The company also offers Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.

Receive ARX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aroa Biosurgery and its competitors with MarketBeat's FREE daily newsletter.

ARX Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
ASX:ARX
CIK
N/A
Fax
N/A
Employees
147,000
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$69.07 million
Price / Cash Flow
2.37
Book Value
A$0.25 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$193.14 million
Optionable
Not Optionable
Beta
0.69
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (ASX:ARX) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners